Expression of ABC-transport proteins in canine mammary cancer: consequences for chemotherapy

K U Honscha1, A Schirmer, A Reischauer

  • 1Institute of Veterinary Physiology, Faculty of Veterinary Medicine, University of Leipzig, Leipzig, Germany. K.honscha@vetmed.uni-leipzig.de

Insights

Drug resistance in canine mammary tumors is often due to ATP-binding cassette (ABC) transporters. These transporters, including multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP), limit chemotherapy effectiveness.

Area of Science:

  • Veterinary Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Drug resistance is a significant challenge in cancer chemotherapy.
  • ATP-binding cassette (ABC) transporters in tumor cells can prevent the accumulation of chemotherapeutic agents.
  • Understanding ABC transporter expression in canine mammary tumors is crucial for effective treatment.

Purpose of the Study:

  • To investigate the mRNA expression of seven ABC-transporters in canine mammary tumors.
  • To functionally analyze the canine breast cancer resistance protein (cBCRP) and its role in drug resistance.
  • To determine the impact of ABC transporter expression on chemotherapy efficacy in canine mammary cancer.

Main Methods:

  • RT-PCR was used to analyze the mRNA expression of seven ABC-transporters in 103 canine mammary tumor samples.
  • Stable transfection of Madin-Darby canine kidney-II cells with cBCRP was performed.
  • MTT viability assays were conducted to assess drug resistance in transfected cells.

Main Results:

  • All tumor samples expressed multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP).
  • High expression rates were observed for MRP7 (97.1%), MRP3 (96.1%), Pgp (92.2%), MRP5 (85.4%), and MRP6 (64.1%).
  • cBCRP-transfected cells exhibited a 5.4-fold resistance to doxorubicin, while methotrexate sensitivity remained unaffected.

Conclusions:

  • The expression of seven different ABC-transporters can contribute to the lack of chemotherapy efficacy in canine mammary cancer.
  • Given its universal expression in canine mammary tumors and induced doxorubicin resistance, cBCRP is a key factor.
  • Doxorubicin may be an inappropriate choice for treating canine mammary cancer due to cBCRP-mediated resistance.

Related Concept Videos

ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
ABC Transporters: Importer01:27

ABC Transporters: Importer

ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...